Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T15:47:20.876Z.
Calculation as of: 2026-10-06T15:47:20.876Z.
Quote observation: 2026-10-06T15:44:39.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a3d1fbdfc20658083391a22a35257b501cad1354629c31eed1b40f8a69f1a870
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Lucid Diagnostics Inc.
Market Cap
$115.36M
EV/EBIT Ratio
N/A
| NAME | MARKET CAP | EV/EBIT RATIO |
|---|---|---|
| Lucid Diagnostics Inc. (LUCD) | $115.36M | N/A |
| BGM Group Ltd. (BGM)vs › | $111.14M | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $116.35M | N/A |
| Genelux Corporation (GNLX)vs › | $116.59M | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $116.34M | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $116.89M | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $117.53M | N/A |
| MaxCyte, Inc. (MXCT)vs › | $114.08M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.99M | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $110.95M | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
